Navigation Links
XTL Provides Update on Phase I Clinical Trial of XTL-2125

VALLEY COTTAGE, New York, June 06, 2007 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. announced today that it has completed the analysis of results from a Phase I clinical trial with XTL-2125 in patients with chronic Hepatitis C. This Phase I trial was a placebo controlled, randomized, dose escalating study, which evaluated the safety, tolerability and antiviral activity of single and multiple doses of XTL-2125. The study enrolled 56 patients into seven cohorts comprised of eight patients each (of which two are placebo patients). Each patient received a single dose, followed by a 14-day multi-dosing regimen commencing one week after the single dose administration. The highest daily multi-dose regimen that was evaluated in the trial was 1800mg per day (600mg three times per day).

The analysis of the data indicates that XTL-2125 was generally well tolerated. However, HCV-RNA viral load reductions in patients treated with XTL-2125 were not significantly different from those observed in the placebo group. Based on these results, XTL has decided to suspend further development of XTL-2125.

XTL's CEO, Ron Bentsur, commented: "The completion of this Phase I trial concludes our research on the XTL legacy compounds that we inherited. Through an aggressive business development effort, XTL's new management team has successfully reinvented the company's product portfolio - with Bicifadine as a lead product in late stage clinical development, and the XTL-DOS program, which is emerging as a very promising program in Hepatitis C. We look forward to an exciting rest of 2007, with the initiation of a late-stage clinical trial with Bicifadine in chronic neuropathic pain, and the initiation of IND-enabling studies with a novel hepatitis C inhibitor from the XTL-DOS program. We will also continue to opportunistically seek to broaden our portfolio through the in-licensing and acquisitions of additional clinical
'"/>




Page: 1 2 3

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
3. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
4. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
5. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
8. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
9. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
10. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
11. NeoPharm Provides Update on LE-SN38 Program
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: XTL Provides Update Phase Clinical Trial XTL
(Date:8/21/2014)... CYBX ) today announced results for the quarter ended ... Operating results for the first quarter of fiscal ... other achievements, include: , Worldwide net product sales of ... net sales of $13.2 million, an increase of 14.5% on ... reached a new high of $58.8 million, an increase of ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium Pharmaceuticals, ... specialty biopharmaceutical company, today announced positive results from ... clostridium histolyticum (or CCH) for the treatment of ... In the Phase 2a trial, all three doses ... (0.84mg)) showed an improvement in the appearance of ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Kentucky blocked the sale of more ...
Breaking Medicine Technology:Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... genetics,(Nasdaq: DCGN ) today announced the filing ... the company,s novel small-molecule modulator,of phosphodiesterase 4 (PDE4), ... compound is being developed as a new and ... loss and cognitive deficits associated,with Alzheimer,s disease and ...
... from the,French Medicine Agency (AFSSAPS) the authorization to ... PL37, its lead compound for oral,treatment of neuropathic ... pain condition, with an estimated,prevalence in the world,s ... most,recent surveys, with many causes such as shingles, ...
Cached Medicine Technology:deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2
(Date:8/21/2014)... Chicago, IL (PRWEB) August 21, 2014 ... its 33rd annual Inc. 500|5000, an exclusive ranking of ... most comprehensive look at the most important segment of ... Timberland, Dell, Domino’s Pizza, LinkedIn, Zillow, and many other ... Inc. 500|5000. , “Centurion is proud to have been ...
(Date:8/21/2014)... MISSOULA, Mont. (PRWEB) August 21, 2014 She ... struck blind and brain injured after a surgery to correct ... “He Works All Things Together…” author Rebecca Strom-Stewart shares her ... misguided good intentions that led to a miscarriage of justice ... trudge through the tunnel of darkness and into the light,” ...
(Date:8/21/2014)... Raton, FL (PRWEB) August 21, 2014 Teen ... people in Boca Raton, FL. The rising numbers of young ... been staggering. To help make a difference in the community, ... provide a valuable resource for teens seeking to overcome something ... to help parents and their teens find the best teen ...
(Date:8/21/2014)... Charleston, SC (PRWEB) August 21, 2014 ... one of seven start-ups selected to participate in ... program provides entrepreneur mentorship, curriculum sessions and valuable ... scalable businesses in the region. Each start-up selected ... and support in order to help businesses grow ...
(Date:8/21/2014)... 21, 2014 InSilico Medicine, ... and addressing the challenges of a rapidly ... for signalome-wide pathway analysis. This new ... analysis of gene expression data obtained using ... in the journal Frontiers in Molecular Biosciences, ...
Breaking Medicine News(10 mins):Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 3Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 4Health News:The Dramatic, Uplifting Story from a Brain Injured Woman 2Health News:New Helpline Provides Hope for Troubled Teens in Boca Raton 2Health News:OncoFinder, a new algorithm for minimizing errors in high-throughput transcriptome analysis 2
... PUA Forums.com, the ... meet and charm women, is now also helping men take it to the next level - ... ... for dating advice that has already helped thousands of men learn how to meet and charm ...
... ... the rage. Today more than ever, people are turning to books on attaining success to ... lumped together, a recent discovery by Steve Paris, CEO of Orne Publishing, is about to turn ... , ...
... , ... days in June, QuickMedical® converted their 11,000 square foot warehouse into a showcase for ... of free food and prizes, the QuickMedical® Open House and Benefit was an event ... ...
... ... web portal that provides a comprehensive view of California public policy and legislative issues. ... tracking in one site. , ... (PRWEB) June 28, 2010 -- The ‘LegisWeb Eye’ launches on July 1st, bringing a new ...
... lower their cholesterol are 30 percent less likely to see ... who do not use the drugs, according to researchers at ... of the drugs were associated with lower risk of recurrence. ... "The findings add another layer of evidence ...
... , SUNDAY, June 27 (HealthDay News) -- Scientists have located ... predisposition for type 2 diabetes, bringing the total number of ... At this point, the findings don,t mean much for patients ... treatments. "From here, to apply this clinically is going ...
Cached Medicine News:Health News:PUA Forums Will Help You Get A Girlfriend 2Health News:Discovery of Napoleon Hill Book Bound to Change Fate for Millions 2Health News:Discovery of Napoleon Hill Book Bound to Change Fate for Millions 3Health News:QuickMedical Open House and Benefit for Seattle Children's Hospital A Resounding Success 2Health News:QuickMedical Open House and Benefit for Seattle Children's Hospital A Resounding Success 3Health News:The 'LegisWeb Eye' Legislative Web Portal Launches on July 1st 2Health News:The 'LegisWeb Eye' Legislative Web Portal Launches on July 1st 3Health News:Statins associated with lower cancer recurrence following prostatectomy 2Health News:More Genes Implicated in Type 2 Diabetes 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: